These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27872452)

  • 1. How to treat ANCA‑associated vasculitis: practical messages from 2016 EULAR/ERA‑EDTA recommendations.
    Sznajd J; Mukhtyar C
    Pol Arch Med Wewn; 2016 Oct; 126(10):781-788. PubMed ID: 27872452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.
    Yates M; Watts RA; Bajema IM; Cid MC; Crestani B; Hauser T; Hellmich B; Holle JU; Laudien M; Little MA; Luqmani RA; Mahr A; Merkel PA; Mills J; Mooney J; Segelmark M; Tesar V; Westman K; Vaglio A; Yalçındağ N; Jayne DR; Mukhtyar C
    Ann Rheum Dis; 2016 Sep; 75(9):1583-94. PubMed ID: 27338776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [De-escalation of therapy in ANCA-associated vasculitides].
    Schinke S; Riemekasten G; Lamprecht P
    Z Rheumatol; 2017 Feb; 76(1):15-20. PubMed ID: 27933390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current guidelines on ANCA-associated vasculitides : Common features and differences].
    Hellmich B
    Z Rheumatol; 2017 Mar; 76(2):133-142. PubMed ID: 27848024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides.
    McGeoch L; Twilt M; Famorca L; Bakowsky V; Barra L; Benseler SM; Cabral DA; Carette S; Cox GP; Dhindsa N; Dipchand CS; Fifi-Mah A; Goulet M; Khalidi N; Khraishi MM; Liang P; Milman N; Pineau CA; Reich HN; Samadi N; Shojania K; Taylor-Gjevre R; Towheed TE; Trudeau J; Walsh M; Yacyshyn E; Pagnoux C;
    J Rheumatol; 2016 Jan; 43(1):97-120. PubMed ID: 26523024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
    Rich EN; Brown KK
    Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for ANCA-associated vasculitides.
    Guillevin L
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
    Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
    Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U
    Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
    Tesar V; Hruskova Z
    Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients.
    Moog P; Probst M; Kuechle C; Hauser C; Heemann U; Thuermel K
    Scand J Rheumatol; 2014; 43(6):519-23. PubMed ID: 25179776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
    Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
    Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.